MM-specific universal CAR T cells

MM-specific universal CAR T cells are a form of chimeric antigen receptor (CAR) T cell therapy engineered to target multiple myeloma (MM) by recognizing antigens specifically expressed on malignant plasma cells. Unlike conventional autologous CAR T therapies, "universal" approaches use allogeneic or gene-edited donor-derived T cells, which can be administered to any patient without the need for individualized manufacturing. These universal CAR T cells are designed to overcome limitations such as manufacturing time and cost, and may include genetic modifications to reduce the risk of graft-versus-host disease and immune rejection. The primary mechanism involves redirecting the cytotoxic activity of engineered T lymphocytes against MM-associated antigens such as B-cell maturation antigen (BCMA), CD19, GPRC5D, CD38, SLAMF7 (CS1), CD138, among others[1][2][3]. This approach is under clinical investigation for patients with relapsed or refractory multiple myeloma.

Other names

Universal CAR-T Cells Targeting Multiple Myeloma